Core Insights - Biotech stocks experienced significant gains in after-hours trading on September 9, 2025, driven by clinical updates, insider buying, and investor conference appearances across several small- and mid-cap companies [1] Company Summaries - **Immutep Ltd. (IMMP)**: Shares rose by 4.37% to $1.67 after-hours, following a decline of 6.98% during regular trading. The stock's rebound was fueled by the acceptance of data from its EFTISARC-NEO Phase II trial for oral presentation at CTOS 2025, focusing on a rare cancer with high unmet need [2][3] - **Nautilus Biotechnology Inc. (NAUT)**: Shares surged by 12.25% to $0.7521 after-hours, recovering from a 4.42% decline in regular trading. The increase was attributed to insider buying by CEO Sujal M. Patel, who purchased 83,500 shares, signaling confidence in the company [4][5] - **Pliant Therapeutics Inc. (PLRX)**: The stock ended regular trading at $1.75, up 1.16%, and jumped 16.00% to $2.03 after-hours. The upcoming third-quarter earnings report on November 6, 2025, is expected to provide updates on its lead candidate targeting idiopathic pulmonary fibrosis [6][7] - **Jin Medical International Ltd. (ZJYL)**: Shares closed at $0.6532, gaining 3.65% during regular trading and rising 7.15% to $0.6999 after-hours. The catalyst for this movement was the announcement of expanded production capabilities in China, aimed at enhancing global delivery of medical equipment [7][8] - **Phio Pharmaceuticals Corp. (PHIO)**: The stock rose 8.20% to $2.64 after-hours, building on a 13.49% increase during regular trading. The momentum was driven by participation in the H.C. Wainwright 27th Annual Global Investment Conference, where updates on its Phase 1b clinical trial for PH-762 will be presented [8][9] - **Kura Oncology Inc. (KURA)**: Shares increased by 6.12% to $8.50 after-hours, following a 1.60% decline in regular trading. The rally was linked to the company's presentation at the H.C. Wainwright conference, highlighting key developments and upcoming regulatory milestones for Ziftomenib [10][11][12]

Company Overview - Nautilus is positioned within the evolving proteomics landscape, offering a unique approach compared to existing platforms [2]. Competitive Landscape - Nautilus differentiates itself from other proteomics platforms, including proteomic sequencing companies like QSI and Encodia, targeted proteomics platforms such as Olink or SomaLogic, nanopore protein sequencing, and protein fingerprinting [2].

Nautilus Biotechnology FY Conference Summary Company Overview - Nautilus Biotechnology is focused on developing a new method for protein analysis, which is crucial for therapeutic development and diagnostics. The company aims to provide comprehensive proteome analysis, differentiating itself from existing proteomics platforms that typically focus on niche solutions [2][4][5]. Key Industry Insights - The current proteomics landscape is limited by the inability to measure proteins accurately, with existing methods only identifying about 10% of proteins in a sample [3]. - Nautilus aims to address this gap by building an end-to-end platform that can analyze the entire proteome from any sample, which is essential for advancing precision medicine and drug development [4][5]. Core Product Features - Nautilus is developing a platform capable of proteoform analysis, which allows for the interrogation of various forms of proteins, including modifications that are critical for understanding diseases like Alzheimer's [6][8][11]. - The company has introduced a method called iterative mapping of proteoform (iMap), which enables massively parallel analysis of proteoforms [6][7]. Development Timeline - Nautilus plans to launch its full proteome solution by the end of 2026, with early analyses already underway with select customers [5][33]. - The company is currently focusing 95% of its resources on broad-scale discovery capabilities, with only 5% on proteoform analysis, indicating a strategic prioritization of immediate revenue opportunities [24][25]. Financial Position - Nautilus has a cash position of approximately $180 million, which it plans to manage prudently to support ongoing development and commercialization efforts [48][49]. Market Potential - The proteomics market is expected to be a multibillion-dollar opportunity, with Nautilus targeting both broad-scale discovery and specific proteoform analysis applications [22][23]. - The company is also exploring partnerships with research institutions, such as the Allen Institute for Brain Science, to validate its technology and expand its market presence [20]. Customer Engagement - Initial interest in Nautilus's capabilities has been strong among key opinion leaders (KOLs) in the academic and nonprofit research sectors, with growing conversations in the pharmaceutical industry [21]. Competitive Landscape - Nautilus aims to differentiate itself from competitors by offering a platform that provides reliable and reproducible data, which is critical for therapeutic and diagnostic development [13][15]. - The company believes that its approach to data collection and analysis will set it apart in the evolving proteomics market, similar to how Illumina became a leader in genomics [51]. Future Outlook - The company anticipates that as proteomics technology evolves, it will democratize access to proteomic data, enabling broader applications in various fields, including neurodegeneration, cardiology, and cancer [50][51]. Conclusion - Nautilus Biotechnology is positioned to make significant advancements in the proteomics field with its innovative platform, strong financial management, and strategic focus on both broad-scale and targeted proteoform analysis. The upcoming launch and partnerships are expected to enhance its market presence and drive future growth.

Core Insights - Nautilus Biotechnology, Inc. is participating in multiple investor conferences to enhance visibility and engagement with investors [1][4] Company Overview - Nautilus Biotechnology is a development stage life sciences company headquartered in Seattle, Washington, with R&D operations in San Carlos, California [3] - The company focuses on creating a platform technology for quantifying and analyzing the complexity of the proteome, aiming to democratize access to proteomics and advance human health and medicine [3] Upcoming Events - Management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 10:50 a.m. Pacific Time [4] - A presentation is scheduled for the Q3 Investor Summit Group Virtual Conference on September 16 at 10:00 a.m. Pacific Time, followed by 1x1 meetings on September 17 [4]

Core Insights - Nautilus Biotechnology, Inc. reported its financial results for Q2 2025, highlighting key performance metrics and future outlook [3]. Financial Performance - The earnings call was held on July 31, 2025, at 8:30 AM ET, with participation from key executives including the CEO and CFO [1]. - The company released its financial results for the quarter ended June 30, 2025, indicating a focus on transparency and communication with investors [3]. Management Commentary - The management team, including the CEO and Chief Scientist, provided insights into the company's strategic direction and operational updates during the call [1][3]. - Forward-looking statements were made regarding the company's future performance, emphasizing the potential for growth and innovation in the biotechnology sector [4].

[PART I. FINANCIAL INFORMATION](index=5&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This section provides the unaudited condensed consolidated financial statements and related notes for the periods ended June 30, 2025, detailing the company's financial position and performance [Item 1. Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements, including balance sheets, statements of operations, and cash flows, for the periods ended June 30, 2025 [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This table provides a snapshot of the company's financial position, detailing assets, liabilities, and equity as of June 30, 2025, and December 31, 2024 Condensed Consolidated Balance Sheet Highlights (Unaudited) | (in thousands) | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $34,457 | $27,646 | | Short-term investments | $113,416 | $102,247 | | Total current assets | $150,725 | $132,826 | | Total assets | $213,189 | $242,743 | | **Liabilities & Stockholders' Equity** | | | | Total current liabilities | $8,137 | $7,632 | | Total liabilities | $32,095 | $34,013 | | Accumulated deficit | $(304,665) | $(273,019) | | Total stockholders' equity | $181,094 | $208,730 | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) This table presents the company's operating expenses, interest income, and net loss for the three and six months ended June 30, 2025, and 2024 Condensed Consolidated Statements of Operations (Unaudited) | (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $10,394 | $12,436 | $21,930 | $25,366 | | General and administrative | $6,703 | $8,353 | $14,011 | $17,030 | | **Total operating expenses** | **$17,097** | **$20,789** | **$35,941** | **$42,396** | | Interest income | $2,080 | $2,798 | $4,311 | $5,675 | | **Net loss** | **$(15,033)** | **$(18,010)** | **$(31,646)** | **$(36,740)** | | Net loss per share | $(0.12) | $(0.14) | $(0.25) | $(0.29) | [Condensed Consolidated Statements of Cash Flows](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This table summarizes the cash flows from operating, investing, and financing activities for the six months ended June 30, 2025, and 2024 Condensed Consolidated Statements of Cash Flows (Unaudited) | (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(27,287) | $(31,723) | | Net cash provided by investing activities | $33,985 | $36,647 | | Net cash provided by financing activities | $113 | $564 | | **Net increase in cash, cash equivalents and restricted cash** | **$6,811** | **$5,488** | [Notes to Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) These notes provide essential details on the company's business, accounting policies, development-stage status, and financial commitments - Nautilus is a **development-stage** biotechnology company focused on its proteomics platform, devoting substantially all resources to R&D, and has not generated any revenue since its inception in 2016[28](index=28&type=chunk) - The company has incurred net operating losses every year since inception and had an accumulated deficit of **$304.7 million** as of June 30, 2025[32](index=32&type=chunk) - Management believes its cash, cash equivalents, and short-term investments of **$147.9 million** as of June 30, 2025, are sufficient to fund operations for at least the next twelve months[33](index=33&type=chunk) - As of June 30, 2025, the company had open purchase commitments for goods and services of **$1.5 million** and total future minimum lease payments of **$35.8 million**[77](index=77&type=chunk)[80](index=80&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=23&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section analyzes the company's financial condition and operational results, highlighting its development-stage status, expense trends, liquidity, and capital resources [Overview](index=23&type=section&id=Overview) This overview describes Nautilus as a development-stage life sciences company focused on its proteomics platform, with no commercialized products or revenue to date - Nautilus is a **development-stage** life sciences company creating a platform technology for quantifying the proteome, with no commercialized products or generated revenue yet[88](index=88&type=chunk)[89](index=89&type=chunk) - The company plans a three-phase commercial launch for its platform, with a broader launch anticipated in **late 2026**, currently in the first phase of research collaborations[92](index=92&type=chunk) [Results of Operations](index=27&type=section&id=Results%20of%20Operations) This section details the company's operating expenses, showing a decrease in research and development and general and administrative costs for the periods presented Comparison of Operating Results (Q2 2025 vs. Q2 2024) | (in thousands) | Q2 2025 | Q2 2024 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Research and development | $10,394 | $12,436 | $(2,042) | (16)% | | General and administrative | $6,703 | $8,353 | $(1,650) | (20)% | | **Total operating expenses** | **$17,097** | **$20,789** | **$(3,692)** | **(18)%** | - The decrease in Q2 2025 operating expenses was driven by lower salaries and benefits from a March 2025 reduction in force, reduced laboratory services, and lower stock-based compensation as initial merger-related grants became fully expensed[110](index=110&type=chunk)[111](index=111&type=chunk) Comparison of Operating Results (Six Months Ended June 30, 2025 vs. 2024) | (in thousands) | H1 2025 | H1 2024 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Research and development | $21,930 | $25,366 | $(3,436) | (14)% | | General and administrative | $14,011 | $17,030 | $(3,019) | (18)% | | **Total operating expenses** | **$35,941** | **$42,396** | **$(6,455)** | **(15)%** | [Liquidity and Capital Resources](index=29&type=section&id=Liquidity%20and%20Capital%20Resources) This section discusses the company's cash position, capital funding strategies, and its recent Nasdaq minimum bid price deficiency notice - As of June 30, 2025, the company had cash, cash equivalents, and investments of **$179.5 million**, which management believes is sufficient to fund operations for at least the next twelve months[117](index=117&type=chunk)[125](index=125&type=chunk) - In February 2024, the company established an "at the market" (ATM) offering program to sell up to **$125.0 million** of common stock, with no shares sold under this program during the first six months of 2025[119](index=119&type=chunk) - On May 2, 2025, the company received a deficiency letter from Nasdaq for its stock price falling below the **$1.00 minimum bid requirement**, with a 180-day compliance period[122](index=122&type=chunk)[123](index=123&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=34&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risks include interest rate fluctuations affecting its investment portfolio and inflation impacting operating costs - The company's main market risks are interest rate risk on its **$179.5 million** in cash and investments, and inflation risk on its operating costs[144](index=144&type=chunk)[145](index=145&type=chunk)[146](index=146&type=chunk) [Item 4. Controls and Procedures](index=35&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2025, with no material changes to internal controls over financial reporting - The CEO and CFO concluded that the company's disclosure controls and procedures were **effective** as of June 30, 2025[148](index=148&type=chunk) [PART II - OTHER INFORMATION](index=36&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) This section covers other information including legal proceedings, risk factors, equity sales, defaults, mine safety, and exhibits [Item 1. Legal Proceedings](index=36&type=section&id=Item%201.%20Legal%20Proceedings) The company may become involved in various claims and legal proceedings in the ordinary course of business - A lawsuit filed by the company in December 2023 against Somalogic, Inc. and the California Institute of Technology concerning a patent dispute was **settled and dismissed in November 2024**[79](index=79&type=chunk) [Item 1A. Risk Factors](index=36&type=section&id=Item%201A.%20Risk%20Factors) This section outlines significant risks to the company's business, including its development-stage status, dependence on platform commercialization, competition, capital needs, and intellectual property protection - The business is entirely dependent on the successful development and commercialization of its Nautilus platform, which remains in the **development stage** and faces significant scientific, technical, and market acceptance challenges[156](index=156&type=chunk)[172](index=172&type=chunk) - The company faces significant competition from large, established life sciences companies with greater financial, manufacturing, and commercial resources[156](index=156&type=chunk)[193](index=193&type=chunk)[194](index=194&type=chunk) - The company anticipates needing to raise **additional capital** to fund its development and commercialization plans, with fundraising potentially impacted by adverse economic conditions[159](index=159&type=chunk)[213](index=213&type=chunk)[214](index=214&type=chunk) - The company faces substantial risks related to obtaining and maintaining sufficient intellectual property protection for its technology and may become involved in costly litigation[160](index=160&type=chunk)[162](index=162&type=chunk)[222](index=222&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=81&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) There were no unregistered sales of equity securities during the period - None[366](index=366&type=chunk) [Item 3. Defaults Upon Senior Securities](index=81&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) There were no defaults upon senior securities during the period - None[367](index=367&type=chunk) [Item 4. Mine Safety Disclosures](index=81&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section is not applicable to the company - None[368](index=368&type=chunk) [Item 5. Other Information](index=81&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the last fiscal quarter - No directors or officers adopted or terminated a Rule 10b5-1 trading plan or other non-Rule 10b5-1 trading arrangement during the quarter[369](index=369&type=chunk) [Item 6. Exhibits](index=82&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including certifications by the Principal Executive Officer and Principal Financial Officer

Financial Data and Key Metrics Changes - Total operating expenses for Q2 2025 were $17.1 million, an 18% decrease from $20.8 million in Q2 2024, attributed to reduced personnel costs and ongoing cost optimization efforts [34] - Research and development expenses decreased to $10.4 million from $12.4 million year-over-year, while general and administrative expenses fell to $6.7 million from $8.4 million [34] - Net loss for the quarter was $15 million compared to $18 million in the prior year period [34] - The company ended the quarter with approximately $179.5 million in cash, cash equivalents, and investments, projecting a cash runway extending through 2027 [34] Business Line Data and Key Metrics Changes - The company reported significant progress in its tau proteoform assay, which is expected to drive future collaborations and insights into neurodegenerative diseases [6][21] - The iterative mapping method demonstrated unprecedented dynamic range and reproducibility, with a median coefficient of variation of 1.5% within experiments and approximately 5% across multiple instruments [13][14] Market Data and Key Metrics Changes - The company is experiencing strong interest from academic, pharma, and nonprofit partners, indicating a growing demand for its proteoform analysis capabilities [26][58] - Feedback from researchers at the Alzheimer's Association International Conference highlighted the need for better understanding of disease progression in Alzheimer's, reinforcing the relevance of the company's technology [25][41] Company Strategy and Development Direction - The company aims to refine and scale its broad scale assay configuration while advancing collaborations for tau and non-tau targets [21][28] - Nautilus is focused on market development for its proteoform analysis, recognizing the need to educate potential customers on the unique capabilities of its technology [30][46] - The company plans to balance resources between targeted proteoform and broad scale development programs to ensure timely progress on key milestones [27][47] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to transform how biology is measured and understood, with a strong belief in the mission and the foundation laid by recent scientific advancements [36] - The management acknowledged the challenges in developing the proteoform market but emphasized the potential for significant revenue growth in the coming years [51] Other Important Information - The company has signed two collaborations with major US research institutes to demonstrate its platform's capabilities and performance with customer samples [27] - The manuscript detailing the company's findings is currently under peer review, with hopes for publication in a high-impact journal [50] Q&A Session Summary Question: Reaction from the field regarding the manuscript and collaborations - Management noted strong interest from the Alzheimer's community for better ways to understand the disease, emphasizing the criticality of proteoforms in this context [41][42] Question: Pipeline of demand and revenue outlook - The company expects a longer development timeline for the proteoform opportunity compared to the more established proteome side, with initial revenue anticipated to start small next year [46][51] Question: Customer interest and collaboration impact - There has been significant interest from academic groups, pharma, and nonprofit research institutes, with early conversations indicating a strong demand for proteoform data [57][58] Question: Updates on probe performance - Management clarified that updates on probe performance will be provided in the coming quarters as the company transitions to a new assay configuration [66]

Core Insights - Nautilus Biotechnology, Inc. reported significant advancements in its proteome analysis platform during Q2 2025, including the publication of a scientific manuscript showcasing novel data generated by its technology [2][3] - The company signed collaborations with major research institutes to utilize its platform for studying Tau proteoforms in relation to Alzheimer's disease, aiming to enhance understanding of disease-relevant biology [3] Financial Performance - Operating expenses for Q2 2025 were $17.1 million, an 18% decrease from $20.8 million in the same period last year, attributed to cost optimization and reduced salaries and professional services [4] - The net loss for Q2 2025 was $15.0 million, compared to a net loss of $18.0 million in the prior year [5] - As of June 30, 2025, the company had cash, cash equivalents, and investments totaling $179.5 million [5] Research and Development - The company continues to focus on both targeted and broadscale proteomic development efforts, demonstrating the effectiveness of its Iterative Mapping method for measuring proteoforms [2] - The collaborations with research institutes are expected to facilitate fundamental advances in understanding Alzheimer's disease progression [3]

Nautilus Biotechnology Q2 2025 Earnings Release [Business Highlights and CEO Commentary](index=1&type=section&id=Business%20Highlights%20and%20CEO%20Commentary) Nautilus Biotechnology advanced its platform development in Q2 2025, publishing its first scientific manuscript validating the 'Iterative Mapping' method and securing two new collaborations for Alzheimer's disease research - The company maintained momentum in both targeted and broadscale proteomic development efforts during the second quarter[3](index=3&type=chunk) - Published the first scientific manuscript with novel data from the Nautilus Platform, introducing and validating the 'Iterative Mapping' method for unprecedented proteoform resolution and breadth[3](index=3&type=chunk) - Signed two collaborations with major research institutes to apply the Nautilus platform and its Tau proteoform assay to Alzheimer's disease research, aiming to advance understanding of disease-relevant biology[4](index=4&type=chunk) [Second Quarter 2025 Financial Results](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Results) Nautilus reported an 18% year-over-year decrease in operating expenses to $17.1 million and a reduced net loss of $15.0 million, maintaining a strong liquidity position with $179.5 million in cash, cash equivalents, and investments Q2 2025 Key Financial Metrics | Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | Operating Expenses | $17.1 million | $20.8 million | -18% | | Net Loss | $15.0 million | $18.0 million | Improvement | - The decrease in operating expenses was attributed to cost optimization, timing of R&D activities, and lower expenses for salaries, stock-based compensation, and professional services[5](index=5&type=chunk) - As of June 30, 2025, the company held **$179.5 million** in cash, cash equivalents, and investments[7](index=7&type=chunk) [Financial Statements](index=3&type=section&id=Financial%20Statements) The financial statements detail Nautilus' financial position as of June 30, 2025, and its performance for the three and six months then ended, including the Condensed Consolidated Balance Sheets, Statements of Operations, and Statements of Cash Flows [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, Nautilus reported total assets of $213.2 million, a decrease from $242.7 million at year-end 2024, with total liabilities slightly decreasing to $32.1 million and total stockholders' equity at $181.1 million Balance Sheet Summary (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash, cash equivalents, and investments | $179,509 | $206,298 | | Total current assets | $150,725 | $132,826 | | Total assets | $213,189 | $242,743 | | Total liabilities | $32,095 | $34,013 | | Total stockholders' equity | $181,094 | $208,730 | [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the three months ended June 30, 2025, Nautilus recorded a net loss of $15.0 million, or ($0.12) per share, an improvement from a net loss of $18.0 million, or ($0.14) per share, in the prior-year period, driven by reduced operating expenses Three Months Ended June 30 (in thousands, except per share data) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | Research and development | $10,394 | $12,436 | | General and administrative | $6,703 | $8,353 | | Total operating expenses | $17,097 | $20,789 | | Net loss | $(15,033) | $(18,010) | | Net loss per share | $(0.12) | $(0.14) | Six Months Ended June 30 (in thousands, except per share data) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | Total operating expenses | $35,941 | $42,396 | | Net loss | $(31,646) | $(36,740) | | Net loss per share | $(0.25) | $(0.29) | [Consolidated Statements of Cash Flows](index=5&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2025, net cash used in operating activities was $27.3 million, an improvement from $31.7 million in the same period of 2024, with net cash provided by investing activities of $34.0 million leading to a net increase in cash and cash equivalents of $6.8 million Six Months Ended June 30 (in thousands) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(27,287) | $(31,723) | | Net cash provided by investing activities | $33,985 | $36,647 | | Net cash provided by financing activities | $113 | $564 | | Net increase in cash, cash equivalents and restricted cash | $6,811 | $5,488 |

Core Insights - Nautilus Biotechnology has entered into an agreement with the Allen Institute to explore the relationship between tau protein and neurodegenerative diseases like Alzheimer's [1][6] - The collaboration aims to identify novel tau proteoforms from human brain tissue and analyze their phosphorylation patterns to better understand Alzheimer's disease progression [2][6] - Nautilus' recent preprint highlights the capabilities of its proteomics platform, which offers unprecedented resolution in studying tau proteoforms, providing insights from brain samples of both cognitively normal and impaired patients [3] Company Overview - Nautilus Biotechnology is a development stage life sciences company based in Seattle, focused on creating a platform technology for proteome analysis [4] - The company's mission is to democratize access to proteomic data and drive advancements in human health and medicine [4] Allen Institute Overview - The Allen Institute is a nonprofit research organization dedicated to addressing significant bioscience questions and promoting open science [5] - It is recognized for its large-scale research initiatives and includes various specialized institutes focused on brain science, cell science, immunology, and neural dynamics [5]